CLDN: Celladon Corporation - Summary | Jitta

Celladon Corporation

NASDAQ:CLDN

Notice
Stock data is unavailable or the company’s delisted.
Price
$17.25
Loss Chance
58.4%
1.20JITTA SCORE
n/a
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (15)
Recent Business Performance (5)
Financial Strength (0)
Return to Shareholders (10)
Competitive Advantage (0)
Jitta Signs
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 84.25% in the last quarter (yoy)
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.20
n/a
2.21
131.87%
COMPANY DESCRIPTION
As of March 22, 2016, Celladon Corporation was acquired by Eiger BioPharmaceuticals, Inc., in a reverse merger transaction. Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a enzyme deficiency in heart failure patients that result in inadequate pumping of the heart. Its MYDICAR product is used to treat patients with systolic heart failure, diastolic heart failure, and advanced heart failure, as well as to treat pulmonary arterial hypertension and arteriovenous fistula maturation failure. The company is also developing membrane-bound form of Stem Cell Factor for the treatment of cardiac ischemic damage; and compounds for the treatment of diabetes and neurodegenerative diseases. Celladon Corporation was founded in 2000 and is headquartered in San Diego, California.